Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial

The Lancet · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles